# CemiplimAb Survivorship Epidemiology

> **NCT03836105** · — · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 287 (actual)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma
- Basal Cell Carcinoma

## Interventions

- **DRUG:** cemiplimab

## Key facts

- **NCT ID:** NCT03836105
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-27
- **Primary completion:** 2025-09-29
- **Final completion:** 2025-09-29
- **Target enrollment:** 287 (ACTUAL)
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03836105

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03836105, "CemiplimAb Survivorship Epidemiology". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03836105. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*